Female Oncology Research Articles

PHYTOCHEMICAL COMPOSITION AND MEDICINAL USE OF COMMON TOOTHWORT (LATHRAEA SQUAMARIA L.)

This paper presents the results of an analysis of the scientific literature on the pharmacognostic study of common toothwort (Lathraea squamaria L.). L. squamaria lacks chlorophyll, reaches a height of 30 cm. Most of the time it develops underground in the form of a branching rhizome (often in the form of a cross), covered with ovoid fleshy scales. A flowering stem with a dense spike-shaped drooping inflorescence with red (with a raspberry tinge) flowers grows briefly in the spring and dies off after flowering. The fruit is a unilocular capsule. Currently in traditional medicine, there is considerable experience in the use of herbs and roots of the сommon toothwort. In traditional medicine, L. squamaria is used for: ascites, dropsy, edema, liver cirrhosis, hepatitis, diseases of the bile ducts and gallbladder, kidney diseases, cysts, uterine myoma and other female gynecological diseases, infertility, prostatitis, prostate adenoma, female oncology and liver organs, osteomyelitis, obesity. The chemical composition of L. squamaria has not been established yet taking into account the modern level of science and technology. Phenylethanoid glycosides, iridium glycoside aucubin and aucuboside ester, 6'-O-glucopyranosyl-aucubin, 6'-O-glucopyranosyl melampyroside, melampyroside, D-mannitol, β-sitosterol and other biologically active compounds were isolated. The desirability of studying with the aim of introducing into the conventional medicine was pointed out. Further study of L. squamaria raw materials aimed to introduce into official medicine is a very promising research field.

Diffuse Large B Cell Lymphoma Presenting as Isolated Peritoneal Lymphomatosis: A Gynecologic Case Report and Review of Literature

Peritoneal disease in female oncology is frequently due to peritoneal carcinomatosis. Gynaecologic presentation due to isolated peritoneal lymphomatosis (PL) is rarely reported. The pathogenesis of de-novo PL is not yet understood, as peritoneum is devoid of native lymphoid tissue. Only two such cases have been reported in the literature till date. This case adds to the present gynaecologic literature as the third case of isolated PL. This case report is about a 61-year-old female with isolated PL—diffuse large B cells, germinal centre subtype, with no lymph node or organ involvement. The patient succumbed to her illness within a month of initial presentation, in spite of early treatment initiation. Isolated PL is an extremely rare and aggressive entity that portends a dismal outcome. Hence, further diagnostic and therapeutic advancement in these subgroups of poor prognostic lymphomas is warranted.

The efficacy and risk of prophylactic entecavir for hepatitis B virus-related hepatocellular carcinonma receiving transcatheter arterial chemoembolization.

388 Background: Hepatitis B virus (HBV) reactivation was reported to be induced by transcatheter arterial chemoembolization (TACE) in HBV-related hepatocellular carcinonma (HCC) patients with a high incidence. The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine. This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE. Methods: A consecutive series of 191 HBV-related HCC patients receiving TACE were analyzed including 44 patients received prophylactic entecavir. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 copies/ml higher than nadir the level, and hepatitis flares due to HBV reactivation were the main endpoints. Results: Patients with or without prophylactic were similar in host factors and the majorities of characteristics regarding to tumor factors, HBV status, liver function and LMR. Notably, cycles of TACE were parallel between the groups. Ten (22.7%) patients receiving prophylactic entecavir reached virologic response. The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p=0.000) and hepatitis flares due to HBV reactivation (0.0% vs 11.6%, p=0.039) compared with patients without prophylaxis. Kaplan-Meier analysis illustrated that the patients in the entecavir group presented significantly improved virologic events free survival (p=0.000) and hepatitis flare free survival (p=0.017). Female and Eastern Cooperative Oncology Group (ECOG) performance status 2 was the only significant predictors for virological events in patients without prophylactic antiviral. Rescue antiviral therapy did not reduce the incidence of hepatitis flares due to HBV reactivation. Conclusions: Prophylactic entecavir presented promising efficacy in HBV-related cancer patients receiving TACE. Lower performance status and female gender might be the predictors for HBV reactivation in these patients.